Table 1:
Characteristics of participants
| Overall | HIV-uninfected | HIV+ | |
|---|---|---|---|
| N | 784 | 291 | 493 |
| Age in years * | 53 (48, 59) | 54 (50, 61) | 52 (47, 57) |
| Race * | |||
| White, non-Hispanic | 447 (57.0%) | 192 (66.0%) | 255 (51.7%) |
| Black, non-Hispanic | 248 (31.6%) | 73 (25.1%) | 175 (35.5%) |
| Other | 89 (11.4%) | 26 (8.9%) | 63 (12.8%) |
| MACS Enrollment Wave * | |||
| Wave 1,2 | 415 (52.9%) | 179 (61.5%) | 236 (47.9%) |
| Wave 3,4 | 369 (47.1%) | 112 (38.5%) | 257 (52.1%) |
| Education * | |||
| High school | 160 (20.4%) | 36 (12.4%) | 124 (25.2%) |
| Some college | 230 (29.3%) | 73 (25.1%) | 157 (31.8%) |
| College Graduate | 394 (50.3%) | 182 (62.5%) | 212 (43.0%) |
| Diabetes | 99 (13.2%) | 28 (10.2%) | 71 (15.0%) |
| Statin therapy | 237 (32.0%) | 89 (33.1%) | 148 (31.4%) |
| Hypertension | 355 (46.8%) | 121 (43.1%) | 234 (49.0%) |
| BMI (kg/meter2) | 25.9 (23.5, 29.4) | 26.7 (24.0, 30.2) | 25.5 (23.0, 28.6) |
| eGFR (ml/min/1.73 m2), median (IQR) | 88.3 (74.7, 102.0) | 88.6 (76.9, 101.5) | 88.1 (73.3, 102.6) |
| Active hepatitis C virus infection * | 64 (8.2%) | 11 (3.8%) | 53 (10.8%) |
| Depressive symptoms (CES-D ≥16) * | 218 (27.8%) | 61 (21.0%) | 157 (31.8%) |
| CES-D score * | 7.0 (2.0, 17.0) | 6.0 (1.0, 13.0) | 8.0 (3.0, 19.0) |
| Antidepressant use at depression assessment * | 185 (23.6%) | 52 (17.9%) | 133 (27.0%) |
| Smoking status * | |||
| Never | 233 (29.7%) | 92 (31.6%) | 141 (28.6%) |
| Former | 331 (42.2%) | 137 (47.1%) | 194 (39.4%) |
| Current | 220 (28.1%) | 62 (21.3%) | 158 (32.0%) |
| Alcohol use last six months * | |||
| None | 156 (19.9%) | 40 (13.7%) | 116 (23.5%) |
| 1 to 3 drinks/week | 406 (51.8%) | 145 (49.8%) | 261 (52.9%) |
| 4 to 13 drinks/week | 161 (20.5%) | 75 (25.8%) | 86 (17.4%) |
| >13 drinks/week | 61 (7.8%) | 31 (10.7%) | 30 (6.1%) |
| Marijuana/hash last six months | |||
| Daily | 62 (7.9%) | 21 (7.2%) | 41 (8.3%) |
| Weekly | 58 (7.4%) | 17 (5.8%) | 41 (8.3%) |
| Monthly | 24 (3.1%) | 11 (3.8%) | 13 (2.6%) |
| Less often/None | 640 (81.6%) | 242 (83.2%) | 398 (80.7%) |
| Poppers last six months | |||
| Daily | 7 (0.9%) | 2 (0.7%) | 5 (1.0%) |
| Weekly | 50 (6.4%) | 20 (6.9%) | 30 (6.1%) |
| Monthly | 47 (6.0%) | 15 (5.2%) | 32 (6.5%) |
| Less often/None | 680 (86.7%) | 254 (87.3%) | 426 (86.4%) |
| Crack/cocaine last six months | |||
| Daily | 3 (0.4%) | 3 (1.1%) | 0 (0.0%) |
| Weekly | 20 (2.6%) | 5 (1.8%) | 15 (3.1%) |
| Monthly | 9 (1.2%) | 2 (0.7%) | 7 (1.5%) |
| Less often/None | 723 (95.8%) | 268 (96.4%) | 455 (95.4%) |
| Injection drug use last six months * | 15 (1.9%) | 1 (0.3%) | 14 (2.8%) |
| GlycA (umol/cl) * | 3.8 (3.5, 4.2) | 3.8 (3.4, 4.1) | 3.8 (3.5, 4.3) |
| CRP (ug/ml) * | 1.2 (0.6, 2.5) | 1.0 (0.5, 1.9) | 1.2 (0.7, 2.7) |
| IL6 (pg/ml) * | 1.4 (0.9, 2.3) | 1.3 (0.9, 2.1) | 1.5 (1.0, 2.5) |
| CCL2 (pg/ml) * | 263.4 (199.9, 336.0) | 237.1 (184.2, 312.3) | 273.3 (210.0, 349.7) |
| sCD163 (ng/ml) * | 618.4 (476.5, 801.1) | 544.5 (426.2, 689.1) | 679.3 (519.2, 872.0) |
| sCD14(ng/ml) * | 1497.2 (1255.8, 1755.5) | 1281.3 (1129.3, 1470.1) | 1614.0 (1409.8, 1898.6) |
| Current CD4+ T-lymphocytes/microliter | 593.0 (417.0, 766.0) | - | 593.0 (417.0, 766.0) |
| Nadir CD4+ | 145 (29.4%) | - | 145 (29.4%) |
| Log 10 Cumulative viral RNA | 1.5 (1.0, 1.6) | - | 1.5 (1.0, 1.6) |
| HIV RNA <200 copies/ml | 430 (87.2%) | - | 430 (87.2%) |
| ART at visit | 452 (91.7%) | - | 452 (91.7%) |
| Cumulative years of ART | 9.2 (6.0, 12.2) | - | 9.2 (6.0, 12.2) |
| Clinical AIDS history | 68 (13.8%) | - | 68 (13.8%) |
*
Denotes p value <0.05 between HIV+ and HIV-negative groups
Values are reported as either Median (interquartile range) or number (percentage)
Abbreviations: BMI=body mass index; eGFR=estimated glomerular filtration rate; ART=antiretroviral therapy; kg=kilograms; ml=milliliters; umol=micromoles; cl=centiliters; ug=micrograms; pg=picograms; ng=nanograms.